Trypsin inhibitors: promising candidate satietogenic proteins as complementary treatment for obesity and metabolic disorders?

The increase in non-communicable chronic diseases has aroused interest in the research of adjuvants to the classic forms of treatments. Obesity and metabolic syndrome are the main targets of confrontation because they relate directly to other chronic diseases. In this context, trypsin inhibitors,...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Principais autores: Morais, Ana Heloneida de Araújo, Lima, Vanessa Cristina Oliveira de, Piuvezam, Grasiela, Maciel, Bruna Leal Lima
Outros Autores: https://orcid.org/0000-0002-6460-911X
Formato: article
Idioma:English
Publicado em: Taylor & Francis
Assuntos:
N-communicable diseases
obesity
satiety response
hormones
trypsin inhibitor
Endereço do item:https://repositorio.ufrn.br/handle/123456789/54664
https://doi.org/10.1080/14756366.2018.1542387
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
id ri-123456789-54664
record_format dspace
spelling ri-123456789-546642023-09-01T20:38:36Z Trypsin inhibitors: promising candidate satietogenic proteins as complementary treatment for obesity and metabolic disorders? Morais, Ana Heloneida de Araújo Lima, Vanessa Cristina Oliveira de Piuvezam, Grasiela Maciel, Bruna Leal Lima https://orcid.org/0000-0002-6460-911X N-communicable diseases obesity satiety response hormones trypsin inhibitor The increase in non-communicable chronic diseases has aroused interest in the research of adjuvants to the classic forms of treatments. Obesity and metabolic syndrome are the main targets of confrontation because they relate directly to other chronic diseases. In this context, trypsin inhibitors, molecules with wide heterologous application, appear as possibilities in the treatment of overweight and obesity due to the action on satiety related mechanisms, mainly in the modulation of satiety hormones, such as chole cystokinin. In addition, trypsin inhibitors have the ability to also act on some biochemical parameters related to these diseases, thus, emerging as potential candidates and promising molecules in the treat ment of the obesity and metabolic syndrome. Thus, the present article proposes to approach, through a systematic literature review, the advantages, disadvantages and viabilities for the use of trypsin inhibitors directed to the treatment of overweight and obesity 2023-09-01T20:38:11Z 2023-09-01T20:38:11Z 2019 article LIMA, Vanessa Cristina Oliveira de. et al. Trypsin inhibitors: promising candidate satietogenic proteins as complementary treatment for obesity and metabolic disorders?. Journal of enzyme inhibition and medicinal chemistry, v. 34, n. 1, p. 405-419, 2019. Disponível em: https://www.tandfonline.com/doi/full/10.1080/14756366.2018.1542387. Acesso em: 5 jul. 2023. https://repositorio.ufrn.br/handle/123456789/54664 https://doi.org/10.1080/14756366.2018.1542387 en Attribution 3.0 Brazil http://creativecommons.org/licenses/by/3.0/br/ application/pdf Taylor & Francis
institution Repositório Institucional
collection RI - UFRN
language English
topic N-communicable diseases
obesity
satiety response
hormones
trypsin inhibitor
spellingShingle N-communicable diseases
obesity
satiety response
hormones
trypsin inhibitor
Morais, Ana Heloneida de Araújo
Lima, Vanessa Cristina Oliveira de
Piuvezam, Grasiela
Maciel, Bruna Leal Lima
Trypsin inhibitors: promising candidate satietogenic proteins as complementary treatment for obesity and metabolic disorders?
description The increase in non-communicable chronic diseases has aroused interest in the research of adjuvants to the classic forms of treatments. Obesity and metabolic syndrome are the main targets of confrontation because they relate directly to other chronic diseases. In this context, trypsin inhibitors, molecules with wide heterologous application, appear as possibilities in the treatment of overweight and obesity due to the action on satiety related mechanisms, mainly in the modulation of satiety hormones, such as chole cystokinin. In addition, trypsin inhibitors have the ability to also act on some biochemical parameters related to these diseases, thus, emerging as potential candidates and promising molecules in the treat ment of the obesity and metabolic syndrome. Thus, the present article proposes to approach, through a systematic literature review, the advantages, disadvantages and viabilities for the use of trypsin inhibitors directed to the treatment of overweight and obesity
author2 https://orcid.org/0000-0002-6460-911X
author_facet https://orcid.org/0000-0002-6460-911X
Morais, Ana Heloneida de Araújo
Lima, Vanessa Cristina Oliveira de
Piuvezam, Grasiela
Maciel, Bruna Leal Lima
format article
author Morais, Ana Heloneida de Araújo
Lima, Vanessa Cristina Oliveira de
Piuvezam, Grasiela
Maciel, Bruna Leal Lima
author_sort Morais, Ana Heloneida de Araújo
title Trypsin inhibitors: promising candidate satietogenic proteins as complementary treatment for obesity and metabolic disorders?
title_short Trypsin inhibitors: promising candidate satietogenic proteins as complementary treatment for obesity and metabolic disorders?
title_full Trypsin inhibitors: promising candidate satietogenic proteins as complementary treatment for obesity and metabolic disorders?
title_fullStr Trypsin inhibitors: promising candidate satietogenic proteins as complementary treatment for obesity and metabolic disorders?
title_full_unstemmed Trypsin inhibitors: promising candidate satietogenic proteins as complementary treatment for obesity and metabolic disorders?
title_sort trypsin inhibitors: promising candidate satietogenic proteins as complementary treatment for obesity and metabolic disorders?
publisher Taylor & Francis
publishDate 2023
url https://repositorio.ufrn.br/handle/123456789/54664
https://doi.org/10.1080/14756366.2018.1542387
work_keys_str_mv AT moraisanaheloneidadearaujo trypsininhibitorspromisingcandidatesatietogenicproteinsascomplementarytreatmentforobesityandmetabolicdisorders
AT limavanessacristinaoliveirade trypsininhibitorspromisingcandidatesatietogenicproteinsascomplementarytreatmentforobesityandmetabolicdisorders
AT piuvezamgrasiela trypsininhibitorspromisingcandidatesatietogenicproteinsascomplementarytreatmentforobesityandmetabolicdisorders
AT macielbrunaleallima trypsininhibitorspromisingcandidatesatietogenicproteinsascomplementarytreatmentforobesityandmetabolicdisorders
_version_ 1777022445705756672

Registros relacionados